AB Science a reçu l’autorisation de l’Agence de Santé Suédoise pour initier une étude confirmatoire de Phase III avec le masitinib dans les formes progressives de la sclérose en plaques
02 févr. 2022 12h13 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’AUTORISATION DE L'AGENCE DE SANTÉ SUÉDOISE POUR INITIER UNE ETUDE CONFIRMATOIRE DE PHASE III AVEC LE MASITINIB DANS LES FORMES PROGRESSIVES DE LA SCLEROSE EN...
AB Science a reçu l’autorisation de l’ANSM pour initier une étude confirmatoire de Phase III avec le masitinib dans les formes progressives de la sclérose en plaques
03 janv. 2022 12h10 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’AUTORISATION DE L’ANSM POUR INITIER UNE ETUDE CONFIRMATOIRE DE PHASE III AVEC LE MASITINIB DANS LES FORMES PROGRESSIVES DE LA SCLEROSE EN PLAQUES Paris, 3...
AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)
03 janv. 2022 12h10 HE
|
AB Science
PRESS RELEASE AB SCIENCE HAS BEEN GRANTED AUTHORIZATION TO INITIATE CONFIRMATORY PHASE III TRIAL OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS BY THE FRENCH HEALTH AUTHORITY (ANSM) Paris,...
Multiple Sclerosis Drugs Market to Reach USD 41.99 Billion by 2028 | Market Projection By Technology, Major key players, Growth, Revenue, CAGR, Regional Analysis, Industry Forecast To 2028
08 nov. 2021 03h56 HE
|
Fortune Business Insights
Pune, India, Nov. 08, 2021 (GLOBE NEWSWIRE) -- The global multiple sclerosis drugs market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to...
Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
06 oct. 2021 08h00 HE
|
Sunshine Biopharma Inc.
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
Social Listening Provides a Gateway to Support and Connect with Multiple Sclerosis Patients in the US
15 sept. 2021 04h53 HE
|
Research and Markets
Dublin, Sept. 15, 2021 (GLOBE NEWSWIRE) -- The "Unlocking Patient Insights in Multiple Sclerosis with Social Listening" report has been added to ResearchAndMarkets.com's offering. Gain a...
Multiple Sclerosis Drugs Market Size 2021-2028 | To Reach USD 41.99 Billion by 2028, Exhibiting a CAGR of 6.3 %
05 juil. 2021 05h37 HE
|
Fortune Business Insights
Pune, India, July 05, 2021 (GLOBE NEWSWIRE) -- The global multiple sclerosis drugs market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to...
AB Science fournit le résumé de la conférence virtuelle qui s’est tenue le 3 juin 2021 suite à l’interruption volontaire des études cliniques du masitinib
08 juin 2021 02h30 HE
|
AB Science
COMMUNIQUE DE PRESSE RESUME DE LA CONFERENCE VIRTUELLE DU 3 JUIN 2021 SUITE A L’INTERRUPTION VOLONTAIRE DES ETUDES CLINIQUES DU MASITINIB REPRISE DE LA COTATION MERCREDI 9 JUIN 2021 Paris, 8 juin...
AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
08 juin 2021 02h30 HE
|
AB Science
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON JUNE 3, 2021 FOLLOWING THE VOLUNTARY HOLD IN THE CLINICAL STUDIES OF MASITINIB RESUMPTION OF TRADING ON WEDNESDAY JUNE 9, 2021 Paris, June 8, 2021,...
Multiple Sclerosis Drugs Market Size 2021 | Is Projected to Reach USD 40.66 Billion by 2027, Exhibiting a CAGR of 7.1% during the Forecast Period
19 mai 2021 07h29 HE
|
Fortune Business Insights
Pune, India, May 19, 2021 (GLOBE NEWSWIRE) -- The global multiple sclerosis market size is set to gain momentum as several prominent pharmaceutical companies are participating in conducting clinical...